PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Analytically validated assays to interrogate biomarker status in clinical samples are crucial for personalized medicine. PTEN is a tumor suppressor commonly inactivated in prostate cancer that has been mechanistically linked to disease aggressiveness. Though deletion of PTEN, as detected by cumbersome FISH spot counting assays, is associated with poor prognosis, few studies have validated immunohistochemistry (IHC) assays to determine whether loss of PTEN protein is associated with unfavorable disease.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Cancer Res

Title: Clinical cancer research : an official journal of the American Association for Cancer Research

Publisher: American Association for Cancer Research (AACR)

ISSN (Electronic): 1557-3265

ISSN (Print): 1078-0432

Publication date (Electronic): Oct 15 2011

Volume: 17

Issue: 20

Affiliations

[1 ] Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

Article

Mid ID: NIHMS320914 Publisher Item ID: 1078-0432.CCR-11-1244

DOI: 10.1158/1078-0432.CCR-11-1244

PMC ID: 3195839

PubMed ID: 21878536

SO-VID: 85862f13-7a02-4e8d-a823-2fcef4210a17

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.